Orphazyme AS (CHIX:ORPHAC) Other Gross PPE : kr0.00 Mil (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Other Gross PPE?

Orphazyme AS's Other Gross PPE for the quarter that ended in Jun. 2022 was kr0.00 Mil.

Orphazyme AS's quarterly Other Gross PPE declined from Jun. 2021 (kr13.93 Mil) to Dec. 2021 (kr2.64 Mil) and declined from Dec. 2021 (kr2.64 Mil) to Jun. 2022 (kr0.00 Mil).

Orphazyme AS's annual Other Gross PPE increased from Dec. 2019 (kr5.87 Mil) to Dec. 2020 (kr6.00 Mil) but then declined from Dec. 2020 (kr6.00 Mil) to Dec. 2021 (kr2.64 Mil).

Orphazyme AS Other Gross PPE Historical Data

The historical data trend for Orphazyme AS's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Other Gross PPE Chart

Orphazyme AS Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Other Gross PPE

Get a 7-Day Free Trial

0.35

0.40

5.87

6.00

2.64

Orphazyme AS Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Other Gross PPE	Get a 7-Day Free Trial									19.79	6.00	13.93	2.64	-

Orphazyme AS Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Orphazyme AS (CHIX:ORPHAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.orphazyme.com

Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (CHIX:ORPHAC) Headlines

No Headlines